Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.609 | A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF OZURIFTAMAB VEDOTIN (BA3021) ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Dr. LOONG Herbert H.F. |
| 2018.422 | A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.585 | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed following Definitive, Platinum-Based, Chemoradiation Therapy (PACIFIC 5) |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2019.518 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2020.515 | Determining Engrailed-2 (EN2) Concentration in Urine Samples for Clinical Development of a Urine Lateral Flow Assay for Screening Urinary Tract Cancers |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2020.366 | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.375 | Prospective Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.198 | Clinical Application of a Personalized Circulating Tumour DNA (ctDNA) Assay for Early Detection of Cancer Relapse |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.523 | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.453 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.513 | A Pilot Study to Establish a Local Next-Generation Sequencing (NGS) Platform Enhanced with Artificial Intelligence (AI) For high Throughput Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2020.022 | Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.296 | A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer | Dr. LOONG Herbert Ho Fung |
| 2020.020 | A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.056 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.386 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms | Dr. LOONG Herbert Ho Fung |
| 2019.376 | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.040 | A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.658 | A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Dr. LOONG Herbert Ho Fung 龍浩鋒 醫生 |
| 2019.457 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.346 | Co-morbidities, healthcare utilization and survival outcomes of patients with soft-tissue and bone sarcomas in Hong Kong |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.565 | A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.524 | Bayer 20810 - A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: LOXO-EXT-17005 - A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers | Dr. LOONG Herbert Ho Fung |
| 2019.541 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.554 | A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.493 | A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Dr. LOONG Herbert Ho Fung |
| 2019.159 | A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2017.347 | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2016.493 | An Open-Label, Multicenter, Phase 1 Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer after Progression on First-Line EGFR TKI Therapy |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2016.104 | A retrospective review of Epidemiology, Treatment Patterns, Prognostic Factors and Survival Outcomes of Sarcoma patients in Hong Kong | Dr. LOONG Herbert Ho Fung |
| 2017.172 | DETECTION AND QUANTIFICATION OF T790M and C797S MUTATIONS VIA DIGITAL DROPLET POLYERMASE CHAIN REACTION (ddPCR) IN LUNG CANCER PATIENTS ON OSIMERTINIB TREATMENT |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2016.076 | An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2025.182 | Effectiveness of Instant Messages-delivered Physical Activity e-Coaching and Training (IMPACT) Intervention on Cancer-Related Cognitive Impairment in Lung Cancer Survivors: A Randomized Controlled Trial | Dr. LOONG Herbert Ho Fung |
| 2024.269 | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Dr. LOONG Herbert Ho Fung |
| 2024.347 | Cross-cultural adaptation and validation of the Oxford dyspnoea word cue set for stimulation of emotional processing in lung cancer patients | Dr. LOONG Herbert Ho Fung |
| 2024.397 | Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | Dr. LOONG Herbert Ho Fung |
| 2024.576 | A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2025.096 | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2024.592 | A Phase 2 Study Evaluating the Efficacy, Safety,Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2025.235 | A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) | Dr. LOONG Herbert Ho Fung |
| 2024.441 | A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1 | Dr. LOONG Herbert Ho Fung |
| 2024.319 | An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Dr. LOONG Herbert Ho Fung |
| 2024.248 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Dr. LOONG Herbert Ho Fung |
| 2022.070 | A Phase 2, Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.074 | A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
Page 160 of 265.